TRENDS AND CONSIDERATIONS IN GLOBAL CARDIOVASCULAR DRUG DEVELOPMENT | Page 13

Conclusion
The impact of cardiovascular disease is increasing with the rise of chronic diseases
like diabetes and obesity, and with the aging of the world’s population. The urgent
need to advance cardiovascular therapy depends on the conduct of more
successful and efficient clinical trials that can access the large patient populations
of emerging countries in Latin America, Eastern Europe and the Asia Pacific. To
implement successful multinational CV trials, drug developers must gain
operational proficiencies primarily focused on understanding local regulatory
environments and treatment landscapes, and making the best use of integrated,
Internet-based research platforms. Mastering the complexities of multinational
development offers the additional benefit of delivering new medicines to the
people of the world’s emerging nations.

References

1

World Health Organization, September 2011. Cardiovascular diseases (CVDs). Fact Sheet

Number 317. Available at: www.who.int/mediacentre/factsheets/fs317/en/index.html/.
2

Olin J, Allie D, Belkin, M, et. al., 2011. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010

performance measures for adults with peripheral artery disease. J Am Coll Cardiol;
56(25):2147-2181.
3

Centers for Disease Control and Prevention, January 2012. Be one in a million this

American Heart Month. Available at: http://www.cdc.gov/features/heartmonth/.
4

U.S. Department of Health and Human Services Administration on Aging, 2011. Aging

statistics. Available at: http://www.aoa.gov/aoaroot/aging_statistics/index.aspx/.
5

Centers for Disease Control and Prevention, Adult Obesity. Available at:

http://www.cdc.gov/obesity/data/adult.html/.
6

International Diabetes Federation, The Global Burden. Available at:

http://www.idf.org/diabetesatlas/5e/the-global-burden/.